Syncromune® Inc. Unveils Groundbreaking Data at ASCO 2025

In a significant breakthrough for cancer treatment, Syncromune® Inc. is gearing up to present compelling findings from its SYNC-T Therapy SV-102 Phase 1 trial. This highly anticipated presentation will take place at the American Society for Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago, running from May 30 to June 3.

A Closer Look at SYNC-T Therapy

Under the title, "Clinical Responses to SYNC-T Therapy: In Situ Personalized Cancer Vaccination with Intratumoral Immunotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)," Dr. Ricky T. Tong, a Clinical Assistant Professor at the Lankenau Institute for Medical Research, will showcase how SYNC-T could change the landscape of cancer care.

What Makes SYNC-T Unique?

SYNC-T is not just another therapy; it’s engineered to synchronize critical components essential for a robust anti-tumor immune response. By leveraging the tumor microenvironment, it strategically infuses a multi-target biologic drug directly into the tumor, enhancing immune activation while minimizing systemic exposure. This approach aims to empower T cells to combat cancer more effectively and develop lasting immunological memory.

The Countdown to ASCO 2025

Mark your calendars! The presentation is set for May 31, 2025, from 3:00 to 6:00 PM CT at McCormick Place. This session, focused on Developmental Therapeutics - Immunotherapy, promises insights that could redefine treatment protocols for mCRPC.

Transforming Cancer Treatments